1. Home
  2. STVN vs CRL Comparison

STVN vs CRL Comparison

Compare STVN & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • CRL
  • Stock Information
  • Founded
  • STVN 1949
  • CRL 1947
  • Country
  • STVN Italy
  • CRL United States
  • Employees
  • STVN N/A
  • CRL N/A
  • Industry
  • STVN Containers/Packaging
  • CRL Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • STVN Consumer Discretionary
  • CRL Health Care
  • Exchange
  • STVN Nasdaq
  • CRL Nasdaq
  • Market Cap
  • STVN 6.2B
  • CRL 7.3B
  • IPO Year
  • STVN 2021
  • CRL 2000
  • Fundamental
  • Price
  • STVN $26.23
  • CRL $152.26
  • Analyst Decision
  • STVN Buy
  • CRL Buy
  • Analyst Count
  • STVN 4
  • CRL 15
  • Target Price
  • STVN $25.13
  • CRL $186.64
  • AVG Volume (30 Days)
  • STVN 414.5K
  • CRL 732.3K
  • Earning Date
  • STVN 11-04-2025
  • CRL 11-05-2025
  • Dividend Yield
  • STVN 0.24%
  • CRL N/A
  • EPS Growth
  • STVN 6.78
  • CRL N/A
  • EPS
  • STVN 0.57
  • CRL N/A
  • Revenue
  • STVN $1,344,798,591.00
  • CRL $4,028,615,000.00
  • Revenue This Year
  • STVN $8.24
  • CRL N/A
  • Revenue Next Year
  • STVN $10.38
  • CRL $1.94
  • P/E Ratio
  • STVN $45.99
  • CRL N/A
  • Revenue Growth
  • STVN 5.28
  • CRL N/A
  • 52 Week Low
  • STVN $17.12
  • CRL $91.86
  • 52 Week High
  • STVN $28.00
  • CRL $230.02
  • Technical
  • Relative Strength Index (RSI)
  • STVN 61.46
  • CRL 40.80
  • Support Level
  • STVN $25.40
  • CRL $152.18
  • Resistance Level
  • STVN $27.41
  • CRL $159.78
  • Average True Range (ATR)
  • STVN 1.33
  • CRL 5.79
  • MACD
  • STVN 0.45
  • CRL -1.08
  • Stochastic Oscillator
  • STVN 80.07
  • CRL 17.49

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Share on Social Networks: